Welcome to BioSeeker Group!

A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

Additional Information

Published Date Apr 25, 2011
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 1147
PDF Fact Sheet View Fact Sheet for the report A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

Regular Price: $1,950.00

Special Price: $975.00

Quick Overview

This report comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 companies, from Ceased to Marketed. The report extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market.

    To find out more about A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This report comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 companies, from Ceased to Marketed. The report extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia. BioSeeker has applied its unique drug assessment methodology to stratify the leukemia pipeline and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of leukemia drugs is split between the 49% which have unique drug target strategies and the other part which have head-to-head target competing leukemia drugs in 41 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the leukemia drugs in general. Contributing to this fact is heavily utilized drug target strategies like: IFNAR2, TOP2A, MS4A1 and CD33.

* Eight out of ten drug target strategies in Phase II development are new to leukemia drugs and at the same time the greatest numbers of new target strategies are found in Phase II (34%) and Phase I development (19%).

* Small molecules, antibodies and proteins are the dominating compound strategies of leukemia drugs, which represent almost 90% of the entire pipeline. Cell therapy based leukemia drugs has the lowest representation of defined target strategy portfolio compared to that of other compound strategies of leukemia drugs.

* The highest number of described drug target strategies of leukemia drugs belongs to Novartis (9), Pfizer (9) and Bristol-Myers Squibb (8).

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any leukemia drug to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 20
4.2 List of Tables 20
5 Introduction 29
5.1 The Scope of this Report 29
5.2 Definitions 32
5.3 Abbreviations 32
6 Consider the Therapeutic Target Among Leukemia Drugs for the Highest Therapeutic Outcome and Return on Investment 33
6.1 Drug Repositioning in Oncology 33
6.2 Introduction to Targets of Leukemia Drugs 34
6.2.1 Antigen Binding Targets 41
6.2.2 Carboxy-lyase Activity Targets 43
6.2.3 Catalytic Activity Targets 44
6.2.4 Cell Adhesion Molecule Activity Targets 53
6.2.5 Chaperone Activity Targets 56
6.2.6 Chemokine Activity Targets 60
6.2.7 Cysteine-type Peptidase Activity Targets 61
6.2.8 Cytokine Activity Targets 66
6.2.9 Deaminase Activity Targets 70
6.2.10 Defense/Immunity Protein Activity Targets 71
6.2.11 DNA Binding Targets 72
6.2.12 DNA Repair Protein Targets 74
6.2.13 DNA Topoisomerase Activity Targets 75
6.2.14 DNA-directed DNA Polymerase Activity Targets 79
6.2.15 DNA-methyltransferase Activity Targets 87
6.2.16 G-protein Coupled Receptor Activity Targets 88
6.2.17 Growth Factor Activity Targets 93
6.2.18 GTPase Activator Activity Targets 98
6.2.19 Hydrolase Activity Targets 99
6.2.20 Kinase Activity Targets 102
6.2.21 Kinase Binding Targets 112
6.2.22 Kinase Regulator Activity Targets 114
6.2.23 Ligand-dependent Nuclear Receptor Activity Targets 115
6.2.24 Ligase Activity Targets 117
6.2.25 Lipid Kinase Activity Targets 123
6.2.26 Lipid Phosphatase Activity Targets 129
6.2.27 Methyltransferase Activity Targets 130
6.2.28 MHC Class I Receptor Activity Targets 131
6.2.29 Molecular Function Unknown Targets 132
6.2.30 Motor Activity Targets 138
6.2.31 Oxidoreductase Activity Targets 140
6.2.32 Phosphoric Diester Hydrolase Activity Targets 146
6.2.33 Phosphorylase Activity Targets 155
6.2.34 Protein Binding Targets 159
6.2.35 Protein Serine/Threonine Kinase Activity Targets 164
6.2.36 Protein Threonine/Tyrosine Kinase Activity Targets 203
6.2.37 Protein Tyrosine Phosphatase Activity Targets 208
6.2.38 Protein-tyrosine Kinase Activity Targets 217
6.2.39 Receptor Activity Targets 238
6.2.40 Receptor Binding Targets 258
6.2.41 Receptor Signaling Complex Scaffold Activity Targets 262
6.2.42 RNA Binding Targets 272
6.2.43 RNA-directed DNA Polymerase Activity Targets 273
6.2.44 Serine-type Peptidase Activity Targets 274
6.2.45 Structural Constituent of Cytoskeleton Targets 276
6.2.46 Superoxide Dismutase Activity Targets 277
6.2.47 T Cell Receptor Activity Targets 279
6.2.48 Transcription Factor Activity Targets 281
6.2.49 Transcription Regulator Activity Targets 301
6.2.50 Transferase Activity Targets 313
6.2.51 Translation Regulator Activity Targets 315
6.2.52 Transmembrane Receptor Activity Targets 317
6.2.53 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 323
6.2.54 Transporter Activity Targets 360
6.2.55 Ubiquitin-specific Protease Activity Targets 363
6.2.56 Other Targets 364
6.3 The Cancer Genome Project and Targets of Leukemia Drugs 367
6.3.1 Targets of Leukemia Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 367
6.4 Structure-based Drug Design in Leukemia Therapeutics is Stimulated by Available Structure Data on Biological Targets 373
6.5 Target-Target Interactions among Identified Targets of Leukemia Drugs 377
6.6 The Drug-Target Competitive Landscape 383
6.7 Protein Expression Levels of Identified Targets of Leukemia Drugs 387
6.8 Pathway Assessment of Leukemia Drugs 392
6.8.1 Tools for Analysis of Cancer Pathways 393
6.8.2 Pathway Assessment 394
7 Emerging New Products to Established Ones: Drug Target Strategies of Leukemia Drugs by their Highest Stage of Development 444
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Leukemia Drugs 447
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Leukemia Drugs 450
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Leukemia Drugs 452
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Leukemia Drugs 458
7.5 Preclinical Development: New and Unique Drug Target Strategies of Leukemia Drugs 463
7.6 Drug Target Strategies of Suspended or Terminated Leukemia Drugs 466
7.7 Target Strategy Development Profiles of Leukemia Drugs 469
7.7.1 Marketed 474
7.7.2 Pre-registration 493
7.7.3 Phase III 494
7.7.4 Phase II 504
7.7.5 Phase I 569
7.7.6 Preclinical 606
7.7.7 Ceased 632
7.8 The Competition Through Close Mechanistic Approximation of Leukemia Drugs 671
8 Compound Strategies at Work: Competitive Benchmarking of Leukemia Drugs by Compound Strategy 679
8.1 Small Molecules 681
8.1.1 Background 681
8.1.2 Target Strategies of Small Molecule Drugs 682
8.2 Peptide & Protein Drugs 700
8.2.1 Background 700
8.2.2 Target Strategies of Peptide and Protein Drugs 701
8.3 Antibodies and Antibody-like Structures 706
8.3.1 Background 706
8.3.2 Target Strategies of Antibody Drugs 706
8.4 Nucleic Acid Therapies 711
8.4.1 Background 711
8.4.2 Target Strategies of Nucleic Acid Drugs 712
8.5 Cell & Gene Therapy 715
8.5.1 Background 715
8.5.2 Target Strategies of Cell and Gene Therapy Drugs 716
8.6 Drug Delivery and Nanotechnology 720
8.6.1 Background 720
8.6.2 Target Strategies of Reformulated Drugs 720
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 722
9 Selecting Subindication for Leukemia Drugs 729
9.1 Acute Lymphocytic Leukemia 730
9.2 Acute Myelogenous Leukemia 735
9.3 Chronic Lymphocytic Leukemia 744
9.4 Chronic Myelogenous Leukemia 750
9.5 Chronic Myelomonocytic Leukemia 756
9.6 Hairy Cell Leukemia 757
9.7 Mast Cell Leukemia 759
9.8 Leukemia (general) 760
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Leukemia Drug Pipeline by Investigator 763
10.1 Competitive Fall-Out Assessment 763
10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 765
10.3 3M Pharmaceuticals 767
10.4 4SC 768
10.5 Abbott 769
10.6 Abiogen 773
10.7 Actinium Pharmaceuticals 774
10.8 Advaxis 776
10.9 AEgera 778
10.10 Agenus 780
10.11 Alexion 782
10.12 Alfa Wassermann 783
10.13 Altor BioScience 785
10.14 Ambit Biosciences 786
10.15 Amgen 789
10.16 Antisoma 790
10.17 Arca biopharma 793
10.18 Ariad 795
10.19 Arno Therapeutics 797
10.20 Array BioPharma 798
10.21 Asahi Kasei Pharma 800
10.22 Ascenta Therapeutics 802
10.23 Astellas 803
10.24 Astex Therapeutics 804
10.25 AstraZeneca 806
10.26 Attenuon 809
10.27 Bayer 810
10.28 Bio-Path Holdings 812
10.29 BioCryst Pharmaceuticals 814
10.30 Bioenvision 815
10.31 Biogen Idec 816
10.32 BioSante 821
10.33 Bioton 822
10.34 Boehringer Ingelheim 824
10.35 Bristol-Myers Squibb 827
10.36 BTG 832
10.37 Callisto Pharmaceuticals 835
10.38 Celator Pharmaceuticals 837
10.39 Celera 839
10.40 Celgene 841
10.41 Cell Therapeutics 843
10.42 Celldex Therapeutics 845
10.43 Cephalon 846
10.44 Choongwae 848
10.45 CJ Corp 849
10.46 Clavis Pharma 851
10.47 Cornerstone Pharmaceuticals 853
10.48 CSL 854
10.49 Curacyte 856
10.50 CureTech 857
10.51 Cyclacel 858
10.52 Cylene Pharmaceuticals 860
10.53 CytImmune Sciences 862
10.54 Cytokinetics 863
10.55 Daiichi Sankyo 865
10.56 Dainippon Sumitomo Pharma 867
10.57 Dara Biosciences 869
Deciphera Pharmaceuticals 870
10.58 DiaMedica 873
10.59 Dong-A 874
10.60 Eleos 877
10.61 Eli Lilly 879
10.62 Emergent BioSolutions 883
10.63 EntreMed 884
10.64 Enzon 886
10.65 EpiCept 888
10.66 Epizyme 889
10.67 Erimos 891
10.68 Esperance Pharmaceuticals 893
10.69 Exelixis 895
10.70 ExonHit Therapeutics 899
10.71 Gemin X Biotechnologies 901
10.72 Genencor 903
10.73 Genentech 905
10.74 Genmab 907
10.75 Genta 910
10.76 Genzyme 912
10.77 Geron 914
10.78 Gilead Sciences 916
10.79 GlaxoSmithKline 919
10.80 GlycoGenesys 923
10.81 GlycoMimetics 924
10.82 Hanmi 925
10.83 Hayashibara 927
10.84 Heber Biotec 930
10.85 Hoffmann-La Roche 932
10.86 IDM Pharma 936
10.87 IkerChem 938
10.88 ImClone Systems 940
10.89 Immune Pharmaceuticals 942
10.90 Immunocore 943
10.91 ImmunoGen 945
10.92 Immunomedics 947
10.93 Incyte Corporation 950
10.94 InDex Pharmaceuticals 952
10.95 Inex 953
10.96 Innate Pharma 954
10.97 Innovive 956
10.98 Insys Therapeutics 958
10.99 Intas Biopharmaceuticals 960
10.100 Isis Pharmaceuticals 962
10.101 Italfarmaco 963
10.102 Johnson & Johnson 964
10.103 KaloBios 966
10.104 Kanisa 968
10.105 Kinex 970
10.106 Kyowa Hakko Kirin 971
10.107 Leo 974
10.108 LFB Biotechnologies 976
10.109 LG Life Sciences 978
10.110 Ligand 981
10.111 Lorus Therapeutics 983
10.112 MAT Biopharma 984
10.113 MaxCyte 986
10.114 MaxoCore Pharmaceuticals 987
10.115 Meda 988
10.116 MediGene 991
10.117 Memgen 992
10.118 Merck & Co 993
10.119 Merck KGaA 995
10.120 MethylGene 997
10.121 Micromet 999
10.122 Mologen 1001
10.123 Nereus Pharmaceuticals 1002
10.124 Nerviano Medical Sciences 1004
10.125 NIH – The US National Institute of Health 1005
10.126 Nippon Shinyaku 1007
10.127 Non-industrial Sources 1009
10.128 Novartis 1013
10.129 Novogen 1020
10.130 Onconova 1021
10.131 OSI Pharmaceuticals 1023
10.132 Otsuka 1024
10.133 Pfizer 1025
10.134 Pharmacyclics 1034
10.135 PharmaMar 1036
10.136 PIERIS Proteolab 1038
10.137 Pierre Fabre 1040
10.138 Piramal 1041
10.139 Portola Pharmaceuticals 1043
10.140 Prochon Biotech 1045
10.141 ProMetic Life Sciences 1047
10.142 Reata Pharmaceuticals 1049
10.143 Reliance Life Sciences 1051
10.144 Rigel 1053
10.145 Sangamo BioSciences 1055
10.146 Sanofi-Aventis 1057
10.147 Santaris Pharma 1060
10.148 Sareum 1062
10.149 SBI Biotech 1064
10.150 SBIO 1065
10.151 Seattle Genetics 1067
10.152 Semafore Pharmaceuticals 1068
10.153 Sepal Pharma 1070
10.154 Servier 1071
10.155 Shenogen 1073
10.156 Shire 1074
10.157 Sidus 1076
10.158 Southern Research Institute 1078
10.159 Spirogen 1080
10.160 Stemline Therapeutics 1081
10.161 SuperGen 1083
10.162 Swedish Orphan Biovitrum 1087
10.163 SymBio Pharmaceuticals 1090
10.164 Symbiotec 1091
10.165 Synageva BioPharma 1092
10.166 Synta Pharmaceuticals 1094
10.167 Syntrix 1096
10.168 Takeda 1098
10.169 Talon Therapeutics 1101
10.170 Targa Therapeutics 1103
10.171 TargeGen 1105
10.172 TeGenero 1107
10.173 Teva 1108
10.174 TopoTarget 1110
10.175 Trion Pharma 1112
10.176 Valeant 1114
10.177 Vertex Pharmaceuticals 1115
10.178 Vion Pharmaceuticals 1118
10.179 VioQuest Pharmaceuticals 1120
10.180 XBiotech 1122
10.181 Xencor 1124
10.182 Yamasa Corporation 1126
10.183 Zenyaku Kogyo 1128
11 Disclaimer 1130
12 Drug Index 1131
13 Company Index 1140

4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Leukemia Drugs 382
Figure 2: The Drug-Target Competitive Landscape of Leukemia Drugs - Large Cluster 384
Figure 3: The Drug-Target Competitive Landscape Leukemia Drugs - Smaller Clusters 385
Figure 4: Head-to-Head Targeting Competitive Landscape of Leukemia Drugs 386
Figure 5: Distribution of Compound Strategies among Leukemia Drugs 722
Figure 6: Primary Sub-cellular Localization of Drug Targets 723

4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Leukemia Drug Pipeline by Stage of Development 29
Table 3: Head to Head Target Competition among Leukemia Drugs 29
Table 4: Overview of Drug Target Strategy Themes 34
Table 5: Terminally Ceased Targets of Leukemia Drugs 35
Table 6: Official Gene Name to Target Profle 36
Table 7: Targets of Leukemia Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 368
Table 8: Identity of Leukemia Drug Targets with Available Biological Structures 373
Table 9: Number of Target-Target Interactions among Targets of Leukemia Drugs 377
Table 10: Available Protein Expression Profiles of Leukemia Drugs Targets 387
Table 11: Pathway Summary 394
Table 12: Drug Targets without any Identified Assigned Pathways 394
Table 13: Pathway Profiles According to BioCarta of Leukemia Drug Targets 396
Table 14: Pathway Profiles According to KEGG of Leukemia Drug Targets 414
Table 15: Pathway Profiles According to NetPath of Leukemia Drug Targets 437
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 444
Table 17: Top Competitive Target Strategies of Leukemia Drugs 445
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Leukemia Drugs 447
Table 19: The Competition Through Close Mechanistic Approximation Between Leukemia Drugs being Marketed or in Pre-registration 448
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Leukemia Drugs 450
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Leukemia Drugs 451
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Leukemia Drugs 452
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Leukemia Drugs 455
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Leukemia Drugs 458
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Leukemia Drugs 461
Table 26: New and Unique Target Strategies in Preclinical Development of Leukemia Drugs 463
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Leukemia Drugs 465
Table 28: Target Strategies of Suspended and Terminated Leukemia Drugs 466
Table 29: Connecting Target Strategy with Its Profile Identification Number 469
Table 30: The Competition Through Close Mechanistic Approximation Among Leukemia Drugs 671
Table 31: Overview of Compound Strategy Competition Among Leukemia Drugs 680
Table 32: Overview of the Competitive Landscape of Small Molecule Based Leukemia Drugs 682
Table 33: Competitive Comparison of Target Strategies of Small Molecule Leukemia Drugs 683
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Leukemia Drugs 690
Table 35: Overview of the Competitive Landscape of Peptide Based Leukemia Drugs 701
Table 36: Pursued Target Strategies of Peptide Based Leukemia Drugs 702
Table 37: Overview of the Competitive Landscape of Protein Based Leukemia Drugs 703
Table 38: Competitive Comparison of Target Strategies of Protein Based Leukemia Drugs 704
Table 39: Pursued Target Strategies of Protein Based Leukemia Drugs 705
Table 40: Overview of the Competitive Landscape of Antibody Based Leukemia Drugs 706
Table 41: Competitive Comparison of Target Strategies of Antibody Based Leukemia Drugs 707
Table 42: Pursued Target Strategies of Antibody Based Leukemia Drugs 708
Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Leukemia Drugs 712
Table 44: Competitive Comparison of Target Strategies of Nucleic Acid Based Leukemia Drugs 713
Table 45: Pursued Target Strategies of Nucleic Acid Based Leukemia Drugs 713
Table 46: Potential Forms of Cell Therapy 715
Table 47: Vectors in Gene Therapy 716
Table 48: Overview of the Competitive Landscape of Cell Therapy Based Leukemia Drugs 716
Table 49: Pursued Target Strategies of Cell Therapy Based Leukemia Drugs 717
Table 50: Overview of the Competitive Landscape of Gene Therapy Based Leukemia Drugs 718
Table 51: Pursued Target Strategies of Gene Therapy Based Leukemia Drugs 719
Table 52:Overview of the Competitive Landscape of Reformulated Leukemia Drugs 720
Table 53: Pursued Target Strategies of Reformulated Leukemia Drugs 721
Table 54: Compound Strategies based on Sub-Cellular Localization of Leukemia Drug Targets 723
Table 55 Competitive Summary by Subindication of Leukemia Drugs 729
Table 56: Target Strategy Development Profiles of Drugs for the Treatment of Acute Lymphocytic Leukemia 730
Table 57: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 733
Table 58: Target Strategy Development Profiles of Drugs for the Treatment of Acute Myelogenous Leukemia 735
Table 59: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 740
Table 60: Target Strategy Development Profiles of Drugs for the Treatment of Chronic Lymphocytic Leukemia 744
Table 61: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 748
Table 62: Target Strategy Development Profiles of Drugs for the Treatment of Chronic Myelogenous Leukemia 750
Table 63: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 753
Table 64: Target Strategy Development Profiles of Drugs for the Treatment of Chronic Myelomonocytic Leukemia 756
Table 65: Target Strategy Development Profiles of Drugs for the Treatment of Hairy Cell Leukemia 757
Table 66: The Competition through Close Mechanistic Approximation between Hairy Cell Leukemia Drugs 758
Table 67: Target Strategy Development Profiles of Drugs for the Treatment of Mast Cell Leukemia 759
Table 68: Target Strategy Development Profiles of Drugs for the Treatment of Leukemia (general) 760
Table 69: The Competition through Close Mechanistic Approximation between Leukemia (general) Drugs 762
Table 70: Example of a Competitive Fall-Out Table (Targeting TOP2A) 764
Table 71: Summary Table of Corporate Changes in the Competitive Landscape of Leukemia Drug Development 765
Table 72: 3M Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 767
Table 73: 4SC’s Included Leukemia Pipeline and Competitive Fall-Out 768
Table 74: Abbott’s Included Leukemia Pipeline and Competitive Fall-Out 769
Table 75: Abiogen’s Included Leukemia Pipeline and Competitive Fall-Out 773
Table 76: Actinium Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 774
Table 77: Advaxis’ Included Leukemia Pipeline and Competitive Fall-Out 776
Table 78: AEgera’s Included Leukemia Pipeline and Competitive Fall-Out 778
Table 79: Agenus’ Included Leukemia Pipeline and Competitive Fall-Out 780
Table 80: Alexion’s Included Leukemia Pipeline and Competitive Fall-Out 782
Table 81: Alfa Wassermann’s Included Leukemia Pipeline and Competitive Fall-Out 783
Table 82: Altor BioScience’s Included Leukemia Pipeline and Competitive Fall-Out 785
Table 83: Ambit Biosciences’ Included Leukemia Pipeline and Competitive Fall-Out 786
Table 84: Amgen’s Included Leukemia Pipeline and Competitive Fall-Out 789
Table 85: Antisoma’s Included Leukemia Pipeline and Competitive Fall-Out 790
Table 86: Arca biopharma’s Included Leukemia Pipeline and Competitive Fall-Out 793
Table 87: Ariad’s Included Leukemia Pipeline and Competitive Fall-Out 795
Table 88: Arno Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 797
Table 89: Array BioPharma’s Included Leukemia Pipeline and Competitive Fall-Out 798
Table 90: Asahi Kasei Pharma’s Included Leukemia Pipeline and Competitive Fall-Out 800
Table 91: Ascenta Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 802
Table 92: Astellas’ Included Leukemia Pipeline and Competitive Fall-Out 803
Table 93: Astex Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 804
Table 94: AstraZeneca’s Included Leukemia Pipeline and Competitive Fall-Out 806
Table 95: Attenuon’s Included Leukemia Pipeline and Competitive Fall-Out 809
Table 96: Bayer’s Included Leukemia Pipeline and Competitive Fall-Out 810
Table 97: Bio-Path Holdings’ Included Leukemia Pipeline and Competitive Fall-Out 812
Table 98: BioCryst Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 814
Table 99: Bioenvision’s Included Leukemia Pipeline and Competitive Fall-Out 815
Table 100: Biogen Idec’s Included Leukemia Pipeline and Competitive Fall-Out 816
Table 101: BioSante’s Included Leukemia Pipeline and Competitive Fall-Out 821
Table 102: Bioton’s Included Leukemia Pipeline and Competitive Fall-Out 822
Table 103: Boehringer Ingelheim’s Included Leukemia Pipeline and Competitive Fall-Out 824
Table 104: Bristol-Myers Squibb’s Included Leukemia Pipeline and Competitive Fall-Out 827
Table 105: BTG’s Included Leukemia Pipeline and Competitive Fall-Out 832
Table 106: Callisto Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 835
Table 107: Celator Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 837
Table 108: Celera’s Included Leukemia Pipeline and Competitive Fall-Out 839
Table 109: Celgene’s Included Leukemia Pipeline and Competitive Fall-Out 841
Table 110: Cell Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 843
Table 111: Celldex Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 845
Table 112: Cephalon’s Included Leukemia Pipeline and Competitive Fall-Out 846
Table 113: Choongwae’s Included Leukemia Pipeline and Competitive Fall-Out 848
Table 114: CJ Corp’s Included Leukemia Pipeline and Competitive Fall-Out 849
Table 115: Clavis Pharma’s Included Leukemia Pipeline and Competitive Fall-Out 851
Table 116: Cornerstone Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 853
Table 117: CSL’s Included Leukemia Pipeline and Competitive Fall-Out 854
Table 118: Curacyte’s Included Leukemia Pipeline and Competitive Fall-Out 856
Table 119: CureTech’s Included Leukemia Pipeline and Competitive Fall-Out 857
Table 120: Cyclacel’s Included Leukemia Pipeline and Competitive Fall-Out 858
Table 121: Cylene Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 860
Table 122: CytImmune Sciences’ Included Leukemia Pipeline and Competitive Fall-Out 862
Table 123: Cytokinetics’ Included Leukemia Pipeline and Competitive Fall-Out 863
Table 124: Daiichi Sankyo’s Included Leukemia Pipeline and Competitive Fall-Out 865
Table 125: Dainippon Sumitomo Pharma’s Included Leukemia Pipeline and Competitive Fall-Out 867
Table 126: Dara Biosciences’ Included Leukemia Pipeline and Competitive Fall-Out 869
Table 127: Deciphera Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 870
Table 128: DiaMedica’s Included Leukemia Pipeline and Competitive Fall-Out 873
Table 129: Dong-A’s Included Leukemia Pipeline and Competitive Fall-Out 874
Table 130: Eleos’ Included Leukemia Pipeline and Competitive Fall-Out 877
Table 131: Eli Lilly’s Included Leukemia Pipeline and Competitive Fall-Out 879
Table 132: Emergent BioSolutions’ Included Leukemia Pipeline and Competitive Fall-Out 883
Table 133: EntreMed’s Included Leukemia Pipeline and Competitive Fall-Out 884
Table 134: Enzon’s Included Leukemia Pipeline and Competitive Fall-Out 886
Table 135: EpiCept’s Included Leukemia Pipeline and Competitive Fall-Out 888
Table 136: Epizyme’s Included Leukemia Pipeline and Competitive Fall-Out 889
Table 137: Erimos’ Included Leukemia Pipeline and Competitive Fall-Out 891
Table 138: Esperance Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 893
Table 139: Exelixis’ Included Leukemia Pipeline and Competitive Fall-Out 895
Table 140: ExonHit Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 899
Table 141: Gemin X Biotechnologies’ Included Leukemia Pipeline and Competitive Fall-Out 901
Table 142: Genencor’s Included Leukemia Pipeline and Competitive Fall-Out 903
Table 143: Genentech’s Included Leukemia Pipeline and Competitive Fall-Out 905
Table 144: Genmab’s Included Leukemia Pipeline and Competitive Fall-Out 907
Table 145: Genta’s Included Leukemia Pipeline and Competitive Fall-Out 910
Table 146: Genzyme’s Included Leukemia Pipeline and Competitive Fall-Out 912
Table 147: Geron’s Included Leukemia Pipeline and Competitive Fall-Out 914
Table 148: Gilead Sciences’ Included Leukemia Pipeline and Competitive Fall-Out 916
Table 149: GlaxoSmithKline’s Included Leukemia Pipeline and Competitive Fall-Out 919
Table 150: GlycoGenesys’ Included Leukemia Pipeline and Competitive Fall-Out 923
Table 151: GlycoMimetics’ Included Leukemia Pipeline and Competitive Fall-Out 924
Table 152: Hanmi’s Included Leukemia Pipeline and Competitive Fall-Out 925
Table 153: Hayashibara’s Included Leukemia Pipeline and Competitive Fall-Out 927
Table 154: Heber Biotec’s Included Leukemia Pipeline and Competitive Fall-Out 930
Table 155: Hoffmann-La Roche’s Included Leukemia Pipeline and Competitive Fall-Out 932
Table 156: IDM Pharma’s Included Leukemia Pipeline and Competitive Fall-Out 936
Table 157: IkerChem’s Included Leukemia Pipeline and Competitive Fall-Out 938
Table 158: ImClone Systems’ Included Leukemia Pipeline and Competitive Fall-Out 940
Table 159: Immune Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 942
Table 160: Immunocore’s Included Leukemia Pipeline and Competitive Fall-Out 943
Table 161: ImmunoGen’s Included Leukemia Pipeline and Competitive Fall-Out 945
Table 162: Immunomedics’ Included Leukemia Pipeline and Competitive Fall-Out 947
Table 163: Incyte Corporation’s Included Leukemia Pipeline and Competitive Fall-Out 950
Table 164: InDex Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 952
Table 165: Inex’s Included Leukemia Pipeline and Competitive Fall-Out 953
Table 166: Innate Pharma’s Included Leukemia Pipeline and Competitive Fall-Out 954
Table 167: Innovive’s Included Leukemia Pipeline and Competitive Fall-Out 956
Table 168: Insys Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 958
Table 169: Intas Biopharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 960
Table 170: Isis Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 962
Table 171: Italfarmaco’s Included Leukemia Pipeline and Competitive Fall-Out 963
Table 172: Johnson & Johnson’s Included Leukemia Pipeline and Competitive Fall-Out 964
Table 173: KaloBios’ Included Leukemia Pipeline and Competitive Fall-Out 966
Table 174: Kanisa’s Included Leukemia Pipeline and Competitive Fall-Out 968
Table 175: Kinex’s Included Leukemia Pipeline and Competitive Fall-Out 970
Table 176: Kyowa Hakko Kirin’s Included Leukemia Pipeline and Competitive Fall-Out 971
Table 177: Leo’s Included Leukemia Pipeline and Competitive Fall-Out 974
Table 178: LFB Biotechnologies’ Included Leukemia Pipeline and Competitive Fall-Out 976
Table 179: LG Life Sciences’ Included Leukemia Pipeline and Competitive Fall-Out 978
Table 180: Ligand’s Included Leukemia Pipeline and Competitive Fall-Out 981
Table 181: Lorus Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 983
Table 182: MAT Biopharma’s Included Leukemia Pipeline and Competitive Fall-Out 984
Table 183: MaxCyte’s Included Leukemia Pipeline and Competitive Fall-Out 986
Table 184: MaxoCore Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 987
Table 185: Meda’s Included Leukemia Pipeline and Competitive Fall-Out 988
Table 186: MediGene’s Included Leukemia Pipeline and Competitive Fall-Out 991
Table 187: Memgen’s Included Leukemia Pipeline and Competitive Fall-Out 992
Table 188: Merck & Co’s Included Leukemia Pipeline and Competitive Fall-Out 993
Table 189: Merck KGaA’s Included Leukemia Pipeline and Competitive Fall-Out 995
Table 190: MethylGene’s Included Leukemia Pipeline and Competitive Fall-Out 997
Table 191: Micromet’s Included Leukemia Pipeline and Competitive Fall-Out 999
Table 192: Mologen’s Included Leukemia Pipeline and Competitive Fall-Out 1001
Table 193: Nereus Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 1002
Table 194: Nerviano Medical Sciences’ Included Leukemia Pipeline and Competitive Fall-Out 1004
Table 195: NIH’s Included Leukemia Pipeline and Competitive Fall-Out 1005
Table 196: Nippon Shinyaku’s Included Leukemia Pipeline and Competitive Fall-Out 1007
Table 197: Non-industrial Sources’ Included Leukemia Pipeline and Competitive Fall-Out 1009
Table 198: Novartis’ Included Leukemia Pipeline and Competitive Fall-Out 1013
Table 199: Novogen’s Included Leukemia Pipeline and Competitive Fall-Out 1020
Table 200: Onconova’s Included Leukemia Pipeline and Competitive Fall-Out 1021
Table 201: OSI Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 1023
Table 202: Otsuka’s Included Leukemia Pipeline and Competitive Fall-Out 1024
Table 203: Pfizer’s Included Leukemia Pipeline and Competitive Fall-Out 1025
Table 204: Pharmacyclics’ Included Leukemia Pipeline and Competitive Fall-Out 1034
Table 205: PharmaMar’s Included Leukemia Pipeline and Competitive Fall-Out 1036
Table 206: PIERIS Proteolab’s Included Leukemia Pipeline and Competitive Fall-Out 1038
Table 207: Pierre Fabre’s Included Leukemia Pipeline and Competitive Fall-Out 1040
Table 208: Piramal’s Included Leukemia Pipeline and Competitive Fall-Out 1041
Table 209: Portola Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 1043
Table 210: Prochon Biotech’s Included Leukemia Pipeline and Competitive Fall-Out 1045
Table 211: ProMetic Life Sciences’ Included Leukemia Pipeline and Competitive Fall-Out 1047
Table 212: Reata Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 1049
Table 213: Reliance Life Sciences’ Included Leukemia Pipeline and Competitive Fall-Out 1051
Table 214: Rigel’s Included Leukemia Pipeline and Competitive Fall-Out 1053
Table 215: Sangamo BioSciences’ Included Leukemia Pipeline and Competitive Fall-Out 1055
Table 216: Sanofi-Aventis’ Included Leukemia Pipeline and Competitive Fall-Out 1057
Table 217: Santaris Pharma’s Included Leukemia Pipeline and Competitive Fall-Out 1060
Table 218: Sareum’s Included Leukemia Pipeline and Competitive Fall-Out 1062
Table 219: SBI Biotech’s Included Leukemia Pipeline and Competitive Fall-Out 1064
Table 220: SBIO’s Included Leukemia Pipeline and Competitive Fall-Out 1065
Table 221: Seattle Genetics’ Included Leukemia Pipeline and Competitive Fall-Out 1067
Table 222: Semafore Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 1068
Table 223: Sepal Pharma’s Included Leukemia Pipeline and Competitive Fall-Out 1070
Table 224: Servier’s Included Leukemia Pipeline and Competitive Fall-Out 1071
Table 225: Shenogen’s Included Leukemia Pipeline and Competitive Fall-Out 1073
Table 226: Shire’s Included Leukemia Pipeline and Competitive Fall-Out 1074
Table 227: Sidus’ Included Leukemia Pipeline and Competitive Fall-Out 1076
Table 228: Southern Research Institute’s Included Leukemia Pipeline and Competitive Fall-Out 1078
Table 229: Spirogen’s Included Leukemia Pipeline and Competitive Fall-Out 1080
Table 230: Stemline Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 1081
Table 231: SuperGen’s Included Leukemia Pipeline and Competitive Fall-Out 1083
Table 232: Swedish Orphan Biovitrum’s Included Leukemia Pipeline and Competitive Fall-Out 1087
Table 233: SymBio Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 1090
Table 234: Symbiotec’s Included Leukemia Pipeline and Competitive Fall-Out 1091
Table 235: Synageva BioPharma’s Included Leukemia Pipeline and Competitive Fall-Out 1092
Table 236: Synta Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 1094
Table 237: Syntrix’s Included Leukemia Pipeline and Competitive Fall-Out 1096
Table 238: Takeda’s Included Leukemia Pipeline and Competitive Fall-Out 1098
Table 239: Talon Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 1101
Table 240: Targa Therapeutics’ Included Leukemia Pipeline and Competitive Fall-Out 1103
Table 241: TargeGen’s Included Leukemia Pipeline and Competitive Fall-Out 1105
Table 242: TeGenero’s Included Leukemia Pipeline and Competitive Fall-Out 1107
Table 243: Teva’s Included Leukemia Pipeline and Competitive Fall-Out 1108
Table 244: TopoTarget’s Included Leukemia Pipeline and Competitive Fall-Out 1110
Table 245: Trion Pharma’s Included Leukemia Pipeline and Competitive Fall-Out 1112
Table 246: Valeant’s Included Leukemia Pipeline and Competitive Fall-Out 1114
Table 247: Vertex Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 1115
Table 248: Vion Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 1118
Table 249: VioQuest Pharmaceuticals’ Included Leukemia Pipeline and Competitive Fall-Out 1120
Table 250: XBiotech’s Included Leukemia Pipeline and Competitive Fall-Out 1122
Table 251: Xencor’s Included Leukemia Pipeline and Competitive Fall-Out 1124
Table 252: Yamasa Corporation’s Included Leukemia Pipeline and Competitive Fall-Out 1126
Table 253: Zenyaku Kogyo’s Included Leukemia Pipeline and Competitive Fall-Out 1128

This report includes 186 companies plus their collaborators:
3M Pharmaceuticals
4SC
Abbott
Abiogen
Actinium Pharmaceuticals
Advaxis
AEgera
Agenus
Alexion
Alfa Wassermann
Altor BioScience
Ambit Biosciences
Amgen
Antisoma
Arca biopharma
Ariad
Arno Therapeutics
Array BioPharma
Asahi Kasei Pharma
Ascenta Therapeutics
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Bayer
BioCryst Pharmaceuticals
Bioenvision
Biogen Idec
Bio-Path Holdings
BioSante
Bioton
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Callisto Pharmaceuticals
Celator Pharmaceuticals
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Cephalon
Choongwae
CJ Corp
Clavis Pharma
Cornerstone Pharmaceuticals
CSL
Curacyte
CureTech
Cyclacel
Cylene Pharmaceuticals
CytImmune Sciences
Cytokinetics
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
DiaMedica
Dong-A
Eleos
Eli Lilly
Emergent BioSolutions
EntreMed
Enzon
EpiCept
Epizyme
Erimos
Esperance Pharmaceuticals
Exelixis
ExonHit Therapeutics
Gemin X Biotechnologies
Genencor
Genentech
Genmab
Genta
Genzyme
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
GlycoMimetics
Hanmi
Hayashibara
Heber Biotec
Hoffmann-La Roche
IDM Pharma
IkerChem
ImClone Systems
Immune Pharmaceuticals
Immunocore
ImmunoGen
Immunomedics
Incyte Corporation
InDex Pharmaceuticals
Inex
Innate Pharma
Innovive
Insys Therapeutics
Intas Biopharmaceuticals
Isis Pharmaceuticals
Italfarmaco
Johnson & Johnson
KaloBios
Kanisa
Kinex
Kyowa Hakko Kirin
Leo
LFB Biotechnologies
LG Life Sciences
Ligand
Lorus Therapeutics
MAT Biopharma
MaxCyte
MaxoCore Pharmaceuticals
Meda
MediGene
Memgen
Merck & Co
Merck KGaA
MethylGene
Micromet
Mologen
Nereus Pharmaceuticals
Nerviano Medical Sciences
NIH
Nippon Shinyaku
Non-industrial source
Novartis
Novogen
Onconova
OSI Pharmaceuticals
Otsuka
Pfizer
Pharmacyclics
PharmaMar
PIERIS Proteolab
Pierre Fabre
Piramal
Portola Pharmaceuticals
Prochon Biotech
ProMetic Life Sciences
Reata Pharmaceuticals
Reliance Life Sciences
Rigel
Sangamo BioSciences
Sanofi-Aventis
Santaris Pharma
Sareum
SBI Biotech
SBIO
Seattle Genetics
Semafore Pharmaceuticals
Sepal Pharma
Servier
Shenogen
Shire
Sidus
Southern Research Institute
Spirogen
Stemline Therapeutics
SuperGen
Swedish Orphan Biovitrum
SymBio Pharmaceuticals
Symbiotec
Synageva BioPharma
Synta Pharmaceuticals
Syntrix
Takeda
Talon Therapeutics
Targa Therapeutics
TargeGen
TeGenero
Teva
TopoTarget
Trion Pharma
Valeant
Vertex Pharmaceuticals
Vion Pharmaceuticals
VioQuest Pharmaceuticals
XBiotech
Xencor
Yamasa Corporation
Zenyaku Kogyo
This report includes 313 cancer drugs. From Ceased to Marketed. Some examples are:
alemtuzumab
amonafide malate
amsacrine
barasertib
belinostat
bisantrene
bosutinib
cladribine
clofarabine
CSF-GM
cytarabine ocfosfate
cytarabine, injectable
dasatinib
daunorubicin
decitabine
elacytarabine
enocitabine
gemtuzumab ozogamicin
histamine dihydrochloride
idarubicin
imatinib mesilate
interferon
interferon (alpha)
interferon (alpha2)
interferon (alpha2a)
interferon (alpha2b)
interferon (alpha2c)
interferon (alpha-N1)
interferon (gamma)
interferon alfa-2b
interferon alpha-2b
lestaurtinib
leukemia vaccine
lumiliximab
midostaurin
mitoxantrone
nilotinib
obinutuzumab
oblimersen sodium
ofatumumab
ON-01910
peginterferon alfa-2b
pentostatin
razoxane
rhIFN-alpha
rituximab
sobuzoxane
tamibarotene
teniposide
tipifarnib
vosaroxin
zorubicin

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market.
    To find out more about A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market
This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma. Learn More


Leukemia - A Therapeutic & Competitive Insight
In the report "Leukemia - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to understand the complex field of leukemia therapeutics. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Angiogenesis and Protein Kinase Inhibitors. Learn More


Triple Analysis: Colorectal Cancer, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Colorectal Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Antibodies). Learn More